BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 23590380)

  • 21. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer.
    Kalantari HR
    Br J Cancer; 2009 Oct; 101(7):1222-3; author reply 1224. PubMed ID: 19755985
    [No Abstract]   [Full Text] [Related]  

  • 22. Sunitinib-aggravated hypertension.
    Rivera F; Benounna M; Sánchez de la Nieta MD
    J Hypertens; 2009 Jul; 27(7):1502-3. PubMed ID: 19542988
    [No Abstract]   [Full Text] [Related]  

  • 23. Cardiotoxicity associated with sunitinib.
    Hariharan S; Lowry S
    Lancet; 2008 Apr; 371(9620):1244-5; author reply 1245. PubMed ID: 18406854
    [No Abstract]   [Full Text] [Related]  

  • 24. Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.
    Vickers MM; Heng DY; Hemmelgarn B; Eigl BJ
    Clin Genitourin Cancer; 2009 Oct; 7(3):E104-6. PubMed ID: 19815480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How does sunitinib cause hypothyroidism?
    Hershman JM; Liwanpo L
    Thyroid; 2010 Mar; 20(3):243-4. PubMed ID: 20187779
    [No Abstract]   [Full Text] [Related]  

  • 26. Reversible posterior leukoencephalopathy syndrome induced by sunitinib.
    Martín G; Bellido L; Cruz JJ
    J Clin Oncol; 2007 Aug; 25(23):3559. PubMed ID: 17687168
    [No Abstract]   [Full Text] [Related]  

  • 27. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.
    O'Donnell PH
    BJU Int; 2011 Oct; 108(8):1284-5. PubMed ID: 21418138
    [No Abstract]   [Full Text] [Related]  

  • 28. Re: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
    van den Meiracker AH; Danser AH; Sleijfer S; Kappers MH
    J Natl Cancer Inst; 2011 Oct; 103(20):1557; author reply 1558. PubMed ID: 21862728
    [No Abstract]   [Full Text] [Related]  

  • 29. [Treatment with sunitinib and hypothyroidism--a case report and overview of literature].
    Kreze A; Stáhalová V; Zadrazilová A; Koskuba J; Kosák M
    Klin Onkol; 2009; 22(4):176-8. PubMed ID: 19731880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sunitinib-induced hand-foot syndrome in a renal cell carcinoma: a sclerodermatous and rheumatoid arthritis-like case.
    Ohtsuka T
    J Dermatol; 2012 Nov; 39(11):943-4. PubMed ID: 22257303
    [No Abstract]   [Full Text] [Related]  

  • 31. Sunitinib-induced acute hemolysis without hypertension: a case report.
    Jain R; Mathew P; Wood CG; Tannir NM
    Clin Genitourin Cancer; 2008 Sep; 6(2):122-3. PubMed ID: 18824436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy.
    van der Veldt AA; van den Eertwegh AJ; Hoekman K; Barkhof F; Boven E
    Ann Oncol; 2007 Oct; 18(10):1747-50. PubMed ID: 17890217
    [No Abstract]   [Full Text] [Related]  

  • 33. Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma.
    Flaig TW; Kim FJ; La Rosa FG; Breaker K; Schoen J; Russ PD
    Invest New Drugs; 2009 Feb; 27(1):83-7. PubMed ID: 18563296
    [No Abstract]   [Full Text] [Related]  

  • 34. Sunitinib-associated lymphocytic thyroiditis without circulating antithyroid antibodies.
    Alexandrescu DT; Popoveniuc G; Farzanmehr H; Dasanu CA; Dawson N; Wartofsky L
    Thyroid; 2008 Jul; 18(7):809-12. PubMed ID: 18631016
    [No Abstract]   [Full Text] [Related]  

  • 35. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
    Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute nephritic syndrome after anti-VEGF therapy for renal cell carcinoma.
    Rolleman EJ; Weening J; Betjes MG
    Nephrol Dial Transplant; 2009 Jun; 24(6):2002-3. PubMed ID: 19332867
    [No Abstract]   [Full Text] [Related]  

  • 38. Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis.
    Park CY
    Anticancer Drugs; 2009 Oct; 20(9):848-9. PubMed ID: 19644356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extensive necrotizing fasciitis associated with sunitinib therapy.
    Piszczek J; Dalton B; Peters T; Ruether D; Urbanski S
    Clin Genitourin Cancer; 2014 Apr; 12(2):e47-9. PubMed ID: 24445249
    [No Abstract]   [Full Text] [Related]  

  • 40. Recurrent scrotal hemangiomas during treatment with sunitinib.
    Tonini G; Intagliata S; Cagli B; Segreto F; Perrone G; Onetti Muda A; Santini D; Persichetti P
    J Clin Oncol; 2010 Dec; 28(35):e737-8. PubMed ID: 20823408
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.